ChromaDex Q2 2023: Net sales $20.3M (+21%), positive Adj EBITDA, raises FY23 guidance to ≥15% growth

Niagen Bioscience, Inc.

2023-Q2 EPS reported -$0.05 revenue$42,879,000

Net sales $20.3M, up 21% YoY; Tru Niagen sales $16.9M (+16%).
Net loss narrowed to $2.2M ($0.03/sh) from $6.4M ($0.09/sh) a year ago.
Gross margin 60.8% (+80bps); sales & marketing expense improved 1,830 bps to 29.6% of sales.
Positive Adjusted EBITDA of $0.2M vs negative $4.7M in Q2 2022; positive operating cash flows.
Raised FY2023 revenue outlook by 2.5% to at least 15% YoY growth.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Niagen Bioscience, Inc. reported the second quarter of 2023 results: revenue $20.3 million, net income $2.2 million, EPS $(0.03) per share. Guidance raised.

Period: the second quarter of 2023
Revenue: $20.3 million
Net income: $2.2 million
EPS: $(0.03) per share
Guidance: raised
Result: reported results

Exact text from the filing

by specific reference in such filing. --- EX-99.1 (EX-99.1) --- ChromaDex Corporation Reports Second Quarter 2023 Financial Results Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended

View on SEC.gov

Browse all earnings releases →

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-028555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.